Plasma levels of amyloid beta and other proinflammatory mediators in patients with age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 253, Issue 8, 2015, Pages 1347-1354

  Guymer, Robyn ^a   Cipriani, Tania ^a   Rittenhouse, Kay D ^c   Lim, Lyndell ^a   Robman, Liubov D ^a   Li, Wenlin ^b   Wang, Wenlian ^b   Deng, Shibing ^b   Banerjee, Poulabi ^d  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b PFIZER INC   (United States)

^c BAYER CORPORATION   (United States)

^d REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Age related macular degeneration (AMD); Amyloid beta; Inflammatory mediators

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C2; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3D; COMPLEMENT FACTOR H; CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; TOLL LIKE RECEPTOR ADAPTOR MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; BIOLOGICAL MARKER;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEOGRAPHIC ATROPHY; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TANDEM MASS SPECTROMETRY; VERY ELDERLY; BLOOD; DRUSEN; PILOT STUDY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; AMYLOID BETA-PEPTIDES; BIOMARKERS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; CROSS-SECTIONAL STUDIES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GEOGRAPHIC ATROPHY; HUMANS; MALE; PILOT PROJECTS; RETINAL DRUSEN; TANDEM MASS SPECTROMETRY; WET MACULAR DEGENERATION;

EID: 84938417001     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-015-2970-x     Document Type: Article

References (45)

1. Hageman GS, Anderson DH, Johnson LV, Hancox LS, Taiber AJ, Hardisty L et al (2005) A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci U S A 102(20):7227–7232
2. Maller J, George S, Purcell S, Fagerness J, Altshuler D, Daly MJ et al (2006) Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 38(9):1055–1059
3. Klein RJ, Zeiss C, Chew EY, Tsai JY, Sackler RS, Haynes C et al (2004) Complement factor H polymorphism in age-related macular degeneration. Science 308(5720):385–389
4. Robman L, Baird PN, Dimitrov PN, Richardson AJ, Guymer RH (2010) C-reactive protein levels and complement factor H polymorphism interaction in age-related macular degeneration and its progression. Ophthalmology 117(10):1982–1928
5. Thakkinstain A, Han P, McEvoy M, Smith W, Hoh J, Magnusson K et al (2006) Systemic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet 15(18):2784–2790
6. Gold B, Merriam JE, Zernant J, Hancox LS, Taiber AH, Gehrs K et al (2006) Variation in factor B(BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38(4):458–462
7. Yates JR, Sepp T, Matharu BK, Khan JC, Thurlby DA, Shahid H et al (2007) Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357(6):553–561
8. Barid PN, Islam FM, Richardson ASH, Cain M, Hunt N, Guymer R (2006) Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration. Invest Ophthalmol Vis Sci 47(10):4194–4198
9. Baird PN, Robman LD, Richardson AJ, Dimitrov PN, Tikellis G, McCarty CA et al (2008) Gene-environment interaction in progression of AMD: the CFH gene, smoking and exposure to chronic infection. Hum Mol Genet 17(9):1299–1305
10. Mullins RF, Russell SR, Anderson DH, Hageman GS (2000) Drusen associated with age and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J 14(7):835–846
11. Johnson LV, Leitner WP, Staples MK, Anderson DH (2001) Complement activation and inflammatory processes in drusen formation and age related macular degeneration. Exp Eye Res 73(6):887–896
12. Anderson DH, Mullins RF, Hageman GS, Johnson LV (2002) A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 134(3):411–431
13. Anderson DH, Talaga KC, Rivest AJ, Barron E, Hageman GS, Johson LV (2004) Characterization of beta amyloid assemblies in drusen: the deposits associated with aging and age-related macular degeneration. Exp Eye Res 78(2):243–256
14. Malek G, Li CM, Guidry C, Medeiros NE, Curcio CA (2003) Apolipoprotein B in cholesterol-containing drusen and basal deposits in human eyes with age-related maculopathy. Am J Pathol 162(2):413–425
15. Dentchev T, Milam AH, Lee VM, Trojanowski JQ, Dunaief JL (2003) Amyloid-beta is found in drusen from some age-related macular degeneration retinas, but not in drusen from normal retinas. Mol Vis 9:184–190
16. Xu H, Chen M, Forrester JV (2009) Para-inflammation in the aging retina. Prog Retin Eye Res 28(5):348–368
17. Boekhoorn SS, Vingerling JR, Witteman JC, Hofman A, de John PT (2007) C-reactive protein level and risk of aging macula disorder: the Rotterdam Study. Arch Ophthalmol 125(10):1396–1401
18. Klein R, Klein BE, Knudtson MD, Wong TY, Shankar A, Tsai MY (2005) Systemic markers of inflammation, endothelial dysfunction, and age-related maculopathy. Am J Ophthalmol 140(1):35–44
19. Scholl HPN, Charbel Issa P, Walier M, Janzer S, Pollok-Kopp B et al (2008) Systemic complement activation in age-related macular degeneration. PLOS ONE. doi:10.1371/jornal.pone.0002593
20. Seddon JM, Gensler G, Milton RC, Klein ML, Rifai N (2004) Association between C-reactive protein and age-related macular degeneration. JAMA 291(6):704–710
21. Seddon JM, George S, Rosner B, Rifai N (2005) Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers. Arch Ophthalmol 123(6):774–782
22. KH W, Tan AG, Rochtchina E, Favaloro EJ, Williams A, Mitchell P et al (2007) Circulating inflammatory markers and hemostatic factors in age-related maculopathy: a population-based case–control study. Invest Ophthalmol Vis Sci 48(5):1983–1988
23. Ohno-Matsui K (2011) Parallel findings in age-related macular degeneration and Alzheimers disease. Prog Retin Eye Res 30:217–238
24. Tzekov R, Mullan M (2014) Vision function abnormalities in Alzheimer disease. Surv Ophthalmol 59:414–433
25. Clemons TE, Rankin MW, McBee WL (2006) Cognitive impairment in the age-related eye disease study: AREDS report no. 16. Arch Ophthalmol 124(4):537–543
26. Klaver CC, Ott A, Hofman A, Assink JJ, Breteler MM, de Jong PT (1999) Is age-related maculopathy associated with Alzheimer’s disease? The Rotterdam Study. Am J Epidemiol 150(9):963–968
27. Zetterberg M, Landgren S, Andersson ME, Palmer MS, Gustafson DR, Skoog I et al (2008) Association of complement factor H Y402H gene polymorphism with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet 147B(6):720–726
28. Jonson LV, Leitner WP, Rivest AJ, Staples MK, Radeke MJ, Anderson DH (2002) The Alzheimer’s A beta peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci U S A 99(18):11930–11935
29. Bradt BM, Kolb WP, Cooper NR (1998) Complement-dependent proinflammatory properties of the Alzheimer’s disease beta-peptide. J Exp Med 188(3):431–438
30. Wang J, Ohno-Matsui K, Yoshida T, Kojima A, Shimada N, Nakahama K et al (2008) Altered function of factor I caused by amyloid beta: implication for pathogenesis of age-related macular degeneration from drusen. J Immunol 181(1):712–720
31. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM (2000) Plasma and cerebrospinal fluid levels of amyloid beta proteins 1–40 and 1–42 in Alzheimer disease. Arch Neurol 57(1):100–105
32. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD et al (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The international ARM epidemiological study group. Surv Ophthalmol 39(5):367–374
33. Reynolds R, Hartnett ME, Atkinson JP, Giclas PC, Rosner B, Seddon JM (2009) Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes. Invest Ophthalmol Vis Sci 50(12):5818–5827
34. Shankar A, Mitchell P, Rochchina E, Tan J, Wang JJ (2007) Association between circulating white blood cell count and long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Am J Epidemiol 165(4):375–382
35. Despriet DD, Klaver CC, Witterman JC, Bergen AA, Kardys I, de Matt MP et al (2006) Complement factor H polymorphism, complement activators, and risk of age-related macular degeneration. JAMA 296(3):301–309
36. Schaumberg DA, Christen WG, Buring JE, Glynn RJ, Rifai N, Ridker PM (2007) High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in women. Arch Ophthalmol 125(3):300–305
37. Vine AK, Stader J, Branham K, Musch DC, Swaroop A (2005) Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. Ophthalmology 112(12):2076–2080
38. McGwin G, Hall TA, Xie A, Owsley C (2005) The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study. Br J Ophthalmol 89(9):1166–1170
39. Sivaprasad S, Adewoyin T, Bailey TA, Dandekar SS, Jenkins S, Webster AR et al (2007) Estimation of systemic complement C3 activity in age-related macular degeneration. Arch Ophthalmol 125(4):515–519
40. Bibl M, Welge V, Esselmann H, Wiltfang J (2012) Stability of amyloid-beta peptides in plasma and serum. Electrophoresis 33(3):445–450
41. Mayeux R, Honig LS, Tang MX, Manly J, Stern Y, Schupf N, Mehta PD (2003) Plasma A[beta]40 and A[beta]42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology 61(9):1185–1190
42. Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, Dartigues JF, Tzourio C, Alperovitch A, Buee L, Amouyel P (2009) Association of plasma amyloid beta with risk of dementia: the prospective Three-City Study. Neurology 73(11):847–853
43. Ertekin-Taner N, Younkin LH, Yager DM, Parfitt F, Baker MC, Asthana S, Hutton ML, Younkin SG, Graff-Radford NR (2008) Plasma amyloid beta protein is elevated in late-onset Alzheimer disease families. Neurology 70(8):596–606
44. Ding JD, Lin J, Mace BE, Herrman R, Sullivan P, Bowes RC (2008) Targeting age-related macular degeneration with Alzheimer’s disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. Vis Res 48(3):339–345
45. Ding JD, Johnson LV, Herrmann R, Farsiu S, Smith SG, Groelle M et al (2011) Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci U S A 108(28):E279–E287